Rani Therapeutics Holdings granted an equity award in the form of a stock option to purchase 2,000,000 shares of its Class A common stock to Nicholas Maestas, its new Chief Financial Officer, as an inducement material to his acceptance of employment. The option, granted on July 17, 2026, has an exercise price of $0.6973 per share, equal to the closing price on the grant date, a ten-year term, and vests over four years with 25% of the shares vesting on the one-year anniversary of his employment start and the remaining shares vesting over the following 36 months in equal installments of whole shares, subject to continued service. The grant was approved by the Compensation Committee of Rani’s Board of Directors under Nasdaq Listing Rule 5635(c)(4) and is subject to the company’s 2026 Equity Inducement Plan.
Rani Therapeutics Holdings IncGrant of stock option to new CFO as inducement; no direct impact on operations or value.